Juan M Jiménez Vacas

This was my last meeting with the @ese-eyes.bsky.social News editorial committee, the newsletter of the early career group of the @esendocrinology.bsky.social
Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!

01.11.2025 14:34 — 👍 3    🔁 2    💬 0    📌 0

Thanks for the support throughout this project and beyond! @prostateukprofs.bsky.social

31.10.2025 21:40 — 👍 1    🔁 0    💬 0    📌 0

Thank you, Craig!

31.10.2025 21:02 — 👍 0    🔁 0    💬 0    📌 0

These results highlight the power of predictive biomarkers to guide precision medicine and pave the way for biomarker-driven clinical trials in advanced prostate cancer.
Huge thanks to everyone involved!
🧵4/4

15.10.2025 13:48 — 👍 0    🔁 0    💬 1    📌 0

🔵 MCL1 + AKT inhibition synergistically induces apoptosis in PTEN-loss/PI3K-activated models → patients with these aberrations may benefit most.
🔵 CDK9 inhibition (fadraciclib) + AKT blockade mirrors MCL1i+AKTi combination effects, offering another therapeutic strategy.
🧵3/4

15.10.2025 13:48 — 👍 0    🔁 0    💬 1    📌 0

We investigated the role of MCL1, a key anti-apoptotic protein, in lethal prostate cancer.

Key findings:
🔵 MCL1 copy number gain occurs in a subset of patients → more aggressive disease & poorer outcomes.
🔵 MCL1-targeted monotherapy may benefit these patients.
🧵2/4

15.10.2025 13:48 — 👍 0    🔁 0    💬 1    📌 0

🚨 Delighted to share our latest paper, from
@asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com
Read here: bit.ly/477pYt7
🧵1/4

15.10.2025 13:48 — 👍 12    🔁 5    💬 1    📌 1

Thank you, Ana! Enjoy London!

15.10.2025 13:25 — 👍 1    🔁 0    💬 0    📌 0

Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social
@prostateukprofs.bsky.social

14.10.2025 16:20 — 👍 5    🔁 2    💬 1    📌 0

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer. Jimenez-Vacas et al. (2025) Nature Communications.

Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer?

A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies.

Grab a ☕ and read: doi.org/10.1038/s414...

14.10.2025 16:02 — 👍 3    🔁 3    💬 0    📌 1